| Name | Title | Contact Details |
|---|
Elanco Animal Health Incorporated is a prominent American pharmaceutical company focused on developing, manufacturing, and marketing medicines and vaccinations for pets and livestock. Established in 1954 as a division of Eli Lilly and Company, Elanco became an independent entity in 2018 and has since grown to be one of the largest independent animal health companies worldwide. The acquisition of Bayer Animal Health in 2020 significantly expanded its size and global reach. Elanco offers a wide range of products aimed at enhancing animal health and productivity. This includes pharmaceuticals and vaccines for livestock and companion animals, nutritional solutions to improve feed efficiency, and data analytics through its Elanco Knowledge Solutions division. The company serves a diverse customer base, including farmers, veterinarians, pet owners, and agricultural stakeholders, all dedicated to improving animal health and food quality. Elancos mission emphasizes the importance of food and companionship in enriching life, reflecting its commitment to animal welfare and innovation in the animal health sector.
Prescos is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Retrophin is a biopharmaceutical company focused on the discovery, acquisition, development and commercialization of drugs for the treatment of debilitating and often life-threatening diseases for which there are currently limited patient options.
Celula Inc is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Tarveda Therapeutics is a clinical stage biopharmaceutical company that takes a novel approach to cancer treatment by creating proprietary Pentarins, which are potent and selective, miniaturized conjugates uniquely designed to drive efficacy through deep and rapid penetration into solid tumors resulting in sustained payload accumulation and cancer cell death. Through our Pentarin platform, we are developing therapeutics to address the limitations of current cancer therapies in solid tumors.